Long-term follow-up of children in the HIVNET 012 perinatal HIV prevention trial: Five-year growth and survival

Journal of Acquired Immune Deficiency Syndromes

Volumn 64, Issue 5, 2013, Pages 464-471

  Owor, Maxensia ^a   Mwatha, Anthony ^b   Donnell, Deborah ^b   Musoke, Philippa ^a   Mmiro, Francis ^a   Allen, Melissa ^c   Jackson, J Brooks ^d   Fowler, Mary Glenn ^d   Guay, Laura A ^e  

^a MAKERERE UNIVERSITY   (Uganda)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Family Health International   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

children; HIVNET 012; long term follow up; perinatal HIV prevention trial

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NEVIRAPINE; ZIDOVUDINE;

ANTHROPOMETRY; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHEMOPROPHYLAXIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE TRANSMISSION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MALE; METHODOLOGY; NEWBORN; PHASE 2 CLINICAL TRIAL; PREGNANCY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; VERTICAL TRANSMISSION; CLINICAL TRIAL; HIV INFECTIONS; PREVENTION AND CONTROL; PROCEDURES; TRANSMISSION;

ANTHROPOMETRY; ANTI-HIV AGENTS; BODY HEIGHT; BODY WEIGHT; CHEMOPREVENTION; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; NEVIRAPINE; PREGNANCY; SURVIVAL ANALYSIS; ZIDOVUDINE;

EID: 84891609220     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000015     Document Type: Article

References (21)

1. Available at: Http://www.unaids.org/en/media/unaids/contentassets/ documents/epidemiology/2012/gr2012/20121120-UNAIDS-Global-Report-2012- en.pdf. Accessed April 5, 2013
2. Moye J, Rich KC, Kalish LA, et al. Natural history of somatic growth in infants born to women infected with human immunodeficiency virus. J Pediatr. 1996;128:58-69
3. Bertolli J, Hsu HW, Sukalac T, et al. Hospitalization trends among children and youths with perinatal human immunodeficiency virus infection 1990-2002. Pediatr Infect Dis J. 2006;25:628-633
4. Tovo PA, de Martino M, Gabiano C, et al. Prognostic factors and survival in children with perinatal HIV-1 infection. The Italian Register for HIV-1 Infections in Children. Lancet. 1992;339:1249-1253
5. European Collaborative Study. Fluctuations in symptoms in HIV infected children: The first 10 years of life. Pediatrics. 2001;108:116-122
6. Blanche S, Tardieu M, Duliege A, et al. Longitudinal study of 94 symptomatic infants with perinatally acquired human immunodeficiency virus infection. Evidence for a bimodal expression of clinical and biological symptoms. Am J Dis Child. 1990;144:1210-1215
7. Taha TE, Kumwenda NI, Broadhead RL, et al. Mortality after the first year of life among human immunodeficiency virus type1-infected and uninfected children. Pediatr Infect Dis J. 1999;18:689-694
8. Taha TE, Graham SM, Kumwenda NI, et al. Morbidity among human immunodeficiency virus-1-infected and -uninfected African children. Pediatrics. 2000;106:E77
9. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and single dose nevirapine compared with zidovudine for prevention of mother to child transmission of HIV- 1 in Kampala, Uganda: 18 months follow up of the HIVNET 012 randomised trial. Lancet. 2003;362:859-868
10. Mbori-Ngacha D, Nduati R, John G, et al. Morbidity and mortality in breast fed and formula fed infants of HIV-1 infected women. JAMA. 2001;286:2413-2420
11. Newell ML, Coovadia H, Cortina-Borja M, et al Ghent International AIDS Society (IAS) Working Group on HIV Infection in Women and Children. Mortality of infected and uninfected infants born to HIV infected mothers in Africa: A pooled analysis. Lancet. 2004;364:1236-1243
12. WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Length/Height-for-Age, Weight-for-Age, Weight-for-Length, Weight-for-Height and Body Mass Index-for-Age: Methods and Development. Geneva, Switzerland: World Health Organization; 2006. Available at: Http://www.who.int/childgrowth/ standards/technical-report/en/index.html. Accessed June 4, 2013
13. Spira R, Lepage P, Dabis F, et al. Natural history of human immunodeficiency virus type 1 infection in children: A five-year prospective study in Rwanda. Pediatrics. 1999;104:e56
14. Bridge A, Kipp W, Konde-Lule J, et al. Nutritional status of young children in AIDS affected households and controls in Uganda. Am J Trop Med Hyg. 2006;74:926-931
15. Newell ML, Borja MC, Peckman C, et al European Collaborative Study. Height weight and growth in children born to mothers with HIV infection in Europe. Pediatrics. 2003;111:e52-e60
16. The state of the world's children 2012. Available at: Http://www.unicef. org/uganda/UNICEF-UGANDA-. Accessed January 10, 2013
17. Mermin J, Ekwaru JP, Liechty CA, et al. Effect of cotrimoxazole prophylaxis, antiretroviral therapy and insecticide treated bed nets on the frequency of malaria in HIV-1 infected adults in Uganda; a prospective cohort study. Lancet. 2006;367:1256-1261
18. Kline M, Paul ME, Bohannon B, et al. Characteristics of children surviving to 5 years of age or older with vertically acquired HIV infection. Pediatr AIDS HIV Infect. 1995;6:350-353
19. Blanche S, Newell ML, Mayaux MJ, et al. Morbidity and mortality in European children vertically infected by HIV-1. The French Pediatric HIV Infection Study Group and European Collaborative Study. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:442-450
20. The European Collaborative Study. Natural history of vertically acquired human immunodeficiency virus-1 infection. Pediatrics. 1994;94:815-819
21. Violari A, Cotton MF, Gib DM, et al CHER Study Team. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008; 359: 2233-2244